HC Wainwright Has Negative Outlook for UNCY Q2 Earnings

Posted by Stanley Muller on Jul 3rd, 2026

Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – HC Wainwright lowered their Q2 2026 earnings estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, June 30th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.32) per share for the quarter, down from their prior estimate of ($0.27). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.45) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at $0.06 EPS, FY2027 earnings at ($0.37) EPS, FY2028 earnings at $3.04 EPS, FY2029 earnings at $4.57 EPS and FY2030 earnings at $5.42 EPS.

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.08).

Other research analysts have also recently issued research reports about the company. Guggenheim reissued a “buy” rating and issued a $37.00 price objective (down from $40.00) on shares of Unicycive Therapeutics in a research note on Wednesday, May 13th. Wall Street Zen lowered Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. Noble Financial lowered their target price on Unicycive Therapeutics from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Wednesday. Weiss Ratings raised Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 9th. Finally, Benchmark cut their price target on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating on the stock in a research note on Wednesday. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $27.40.

Check Out Our Latest Research Report on UNCY

Unicycive Therapeutics Stock Performance

Unicycive Therapeutics stock opened at $5.73 on Friday. The company has a 50 day moving average price of $7.43 and a 200-day moving average price of $6.81. Unicycive Therapeutics has a fifty-two week low of $3.71 and a fifty-two week high of $8.74. The company has a market capitalization of $156.94 million, a PE ratio of -2.59 and a beta of 1.79.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of large investors have recently bought and sold shares of UNCY. JPMorgan Chase & Co. lifted its holdings in Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after buying an additional 21,525 shares during the period. Lazard Asset Management LLC bought a new stake in Unicycive Therapeutics during the 2nd quarter valued at $55,000. Vanguard Group Inc. increased its holdings in shares of Unicycive Therapeutics by 8.7% in the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after acquiring an additional 52,925 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at $512,000. Finally, Citadel Advisors LLC bought a new position in shares of Unicycive Therapeutics in the 3rd quarter worth $182,000. Institutional investors own 40.42% of the company’s stock.

Key Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

Negative Sentiment: Investors are reacting to reports that Unicycive received a second FDA Complete Response Letter, with articles saying the agency cited third-party manufacturing deficiencies. That keeps regulatory uncertainty high and appears to be the main pressure on the stock. Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
Negative Sentiment: Multiple law firms, including Kirby McInerney, Bragar Eagel & Squire, and Block & Leviton, announced securities-fraud investigations tied to the FDA update, which can add overhang and worsen investor sentiment. UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT
Negative Sentiment: HC Wainwright and Noble Financial sharply reduced near-term earnings estimates for 2026 and 2027, signaling more caution around the company’s path to profitability even though both firms kept bullish ratings. MarketBeat UNCY analyst updates
Neutral Sentiment: Despite the estimate cuts, analysts such as HC Wainwright and Noble Financial still have Buy/Outperform ratings and price targets well above the current share price, which may help limit downside if investors focus on longer-term commercialization potential. MarketBeat UNCY analyst updates

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Earnings History and Estimates for Unicycive Therapeutics (NASDAQ:UNCY)

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.